There are multiple current and prior research studies on pediatric MS in the US and around the world, including a variety of topics, such as including the natural history and epidemiology of MS in children, disease pathophysiology, characterization of genetic associations and environmental and modifiable biological influences, diagnostic criteria and disease monitoring with biomarkers, and treatments. The first phase III study of a disease-modifying treatment for MS in children was opened in 2013, and continues to enroll patients and collect important safety data and outcome measures to determine the possibility of future wider approval for use in children with MS. Other future phase III studies in children for other DMTs are likely as well in the near future.
Studies investigating the causes of pediatric MS:
Clinical trials in pediatric MS:
- Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
- Adherence in Pediatric Multiple Sclerosis
- Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
- Safety and Efficacy of Fingolimod in Pediatric Patients with Multiple Sclerosis
- PK and PD Study of Natalizumab in Pediatric Subjects with RRMS
- Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (TERIKIDS)
- Safety and Efficacy of Fingolimod in Pediatric Patients with Multiple Sclerosis (PARADIGMS)